Key Ideas

Fibrolamellar hepatocellular carcinoma is a rare liver cancer that strikes young people without the usual liver disease risk factors, and it has no systemic therapy proven to extend survival. A recent case illustrates both the diagnostic hallmarks of this cancer and the trial-and-error nature of treating it, given how little dedicated evidence exists.

An Unusual Liver Cancer in an Unlikely Patient

A 34-year-old woman with no significant medical history and no history of alcohol use, smoking, or drug use presented with progressive abdominal pain, early fullness after eating, nausea, and unintended weight loss. Imaging revealed a large mass, eventually measuring 16 centimeters, involving both lobes of her liver and encasing the portal vein; a liver biopsy confirmed moderately differentiated hepatocellular carcinoma, and molecular testing identified the DNAJB1-PRKACA gene fusion characteristic of fibrolamellar carcinoma. Given the extent of disease and its closeness to major blood vessels, surgery wasn't an option, and she began systemic therapy with the STRIDE regimen (durvalumab and tremelimumab).

Her course illustrates how unpredictable treatment can be in a cancer this rare. She developed immune-related liver inflammation requiring a prolonged steroid taper and treatment break, then a bile duct blockage requiring a procedure to place a stent. By the time she resumed scanning, her tumor had grown to over 19 centimeters with new lymph node involvement. She switched to gemcitabine and oxaliplatin chemotherapy, which controlled her disease for a period before slight progression prompted the addition of lenvatinib, a targeted therapy. Her most recent scans show improvement, with a favorable trend in a key tumor marker, and she remains on this combination.

A Cancer of the Young, With No Playbook

Fibrolamellar hepatocellular carcinoma accounts for less than one percent of primary liver cancers and typically affects people between the ages of 5 and 35, unlike typical hepatocellular carcinoma, which usually arises in the setting of cirrhosis or chronic viral hepatitis in older adults. It has no identified environmental or lifestyle risk factors and is defined by the DNAJB1-PRKACA gene fusion. When surgical resection is possible, it remains the only treatment offering a real chance at cure; for unresectable disease, liver transplantation or local, liver-directed therapies can be considered if the cancer hasn't spread beyond the liver.

For metastatic disease, no systemic therapy has been shown in a trial to extend survival, which makes choosing a treatment regimen genuinely difficult. The limited evidence that exists comes from small case reports and series describing gemcitabine and oxaliplatin (with or without lenvatinib added), checkpoint immunotherapy, and, with even more limited data, older combinations like FOLFOX or 5-fluorouracil with interferon alpha. Given how sparse the evidence base is, seeking a second opinion at a center experienced with this rare cancer, pursuing clinical trial options, and considering molecular tumor profiling are all encouraged wherever feasible; in this case, the patient was unfortunately unable to access outside evaluation for a second opinion, clinical trial screening, or transplant assessment.

For Patients

If you or a loved one, particularly someone young and without typical liver disease risk factors, is diagnosed with a liver mass, ask whether fibrolamellar hepatocellular carcinoma has been considered, since it can occur in patients who wouldn't otherwise be thought of as at risk for liver cancer. If this diagnosis is confirmed, understand that there is no single standard systemic treatment if the cancer can't be removed surgically, and that treatment decisions will likely draw on a limited base of case reports rather than large clinical trials. Because of how rare this cancer is, it's worth asking your care team about the possibility of a second opinion at a center with specific experience treating fibrolamellar carcinoma, as well as about eligibility for any active clinical trials, ideally as early as possible in your treatment course.

Key Takeaways

  • Fibrolamellar hepatocellular carcinoma is a rare cancer, typically affecting people aged 5 to 35, without the usual risk factors for liver cancer.

  • It is defined by the DNAJB1-PRKACA gene fusion and has no established, survival-extending systemic therapy for metastatic disease.

  • Surgical resection remains the primary path to potential cure; unresectable disease may still be eligible for liver transplantation or local therapy if confined to the liver.

  • Treatment for metastatic disease is guided largely by small case series, including gemcitabine/oxaliplatin (with or without lenvatinib) and checkpoint immunotherapy.

  • Given the rarity of this cancer, early consideration of second opinions, clinical trial screening, and molecular profiling is encouraged.